Day One Biopharmaceuticals (DAWN) News Today $7.19 -0.03 (-0.42%) Closing price 04:00 PM EasternExtended Trading$7.20 +0.00 (+0.07%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Fmr LLCFmr LLC increased its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 73.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,887,467 shares of thApril 15 at 3:58 AM | marketbeat.comNorges Bank Acquires Shares of 169,000 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Norges Bank bought a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 169,000 shares of the company's stock, valued at approximatelyApril 14 at 3:31 AM | marketbeat.com100,735 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by CenterBook Partners LPCenterBook Partners LP acquired a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 100,735 shares of the company's stock, valued at approximatelyApril 13 at 6:16 AM | marketbeat.comTrexquant Investment LP Purchases New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Trexquant Investment LP purchased a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 87,972 shares of the company's stock, valued at approximately $1,115,000. Trexquant InvesApril 13 at 4:46 AM | marketbeat.comVanguard Group Inc. Lowers Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Vanguard Group Inc. cut its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,848,923 shares of the company's stock after sellApril 13 at 3:40 AM | marketbeat.comDay One Biopharmaceuticals Pullback Is A Potential Buying OpportunityApril 11, 2025 | seekingalpha.comDay One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comExodusPoint Capital Management LP Buys Shares of 215,137 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)ExodusPoint Capital Management LP purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 215,137 shares of thApril 9, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year Low - Here's What HappenedDay One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year Low - What's Next?April 9, 2025 | marketbeat.comHC Wainwright Analysts Decrease Earnings Estimates for DAWNDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Investment analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Day One Biopharmaceuticals in a research report issued on Thursday, April 3rd. HC Wainwright analyst A. Maldonado now anticipates that the companyApril 8, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Earns Buy Rating from HC WainwrightApril 6, 2025 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)HC Wainwright restated a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday.April 5, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $32.29 Average Target Price from AnalystsApril 5, 2025 | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of "Buy" by BrokeragesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has been given an average rating of "Buy" by the eight research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. ThApril 3, 2025 | marketbeat.comJonesTrading Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)April 2, 2025 | markets.businessinsider.comDay One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year Low - Should You Sell?Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year Low - Here's What HappenedApril 1, 2025 | marketbeat.comPictet Asset Management Holding SA Increases Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Pictet Asset Management Holding SA raised its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 17.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,490,064 shares of the company's stock after buying an addiApril 1, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Holdings Lifted by BIT Capital GmbHBIT Capital GmbH increased its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 41.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 171,714 shares of the company'sMarch 28, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given New $27.00 Price Target at The Goldman Sachs GroupThe Goldman Sachs Group reduced their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday.March 26, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Position Boosted by Bank of New York Mellon CorpBank of New York Mellon Corp lifted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 43.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 244,829 shares of the company's stock after purchasing an additional 74,March 20, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Invests $525,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Skandinaviska Enskilda Banken AB publ acquired a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 41,771 shares ofMarch 18, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 1.7% - Here's WhyDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 1.7% - What's Next?March 15, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low - Should You Sell?Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low - What's Next?March 12, 2025 | marketbeat.comJackson Creek Investment Advisors LLC Buys Shares of 103,592 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Jackson Creek Investment Advisors LLC bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 103,592 shares of the company's stock, valued at appMarch 8, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Buy" from BrokeragesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has earned a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rMarch 8, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 5.5% on Analyst DowngradeDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 5.5% Following Analyst DowngradeMarch 7, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up - Here's WhyDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up - Time to Buy?March 6, 2025 | marketbeat.comJPMorgan Chase & Co. Has Lowered Expectations for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock PriceJPMorgan Chase & Co. lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research report on Wednesday.March 6, 2025 | marketbeat.comDay One Biopharmaceuticals price target lowered to $34 from $39 at JPMorganMarch 5, 2025 | markets.businessinsider.comDay One Biopharmaceuticals, Inc. (DAWN): A Bull Case TheoryMarch 5, 2025 | msn.comDay One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year Low - What's Next?Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year Low - Here's WhyMarch 4, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for DAWN EarningsDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - HC Wainwright lifted their Q1 2025 earnings per share estimates for Day One Biopharmaceuticals in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Maldonado now anticipates that the company will post eaMarch 1, 2025 | marketbeat.comWhat is Wedbush's Forecast for DAWN Q1 Earnings?Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for Day One Biopharmaceuticals in a report released on Wednesday, February 26th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.43) per shaMarch 1, 2025 | marketbeat.comOppenheimer Sticks to Their Hold Rating for Day One Biopharmaceuticals (DAWN)February 27, 2025 | markets.businessinsider.comDay One price target lowered to $30 from $34 at JonesResearchFebruary 27, 2025 | markets.businessinsider.comDay One Biopharmaceuticals (NASDAQ:DAWN) Posts Earnings Results, Misses Estimates By $0.34 EPSDay One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34).February 26, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Announces Earnings Results, Misses Estimates By $0.34 EPSDay One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34).February 26, 2025 | marketbeat.comWedbush Reiterates Outperform Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)Wedbush reaffirmed an "outperform" rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday.February 26, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low Following Weak EarningsDay One Biopharmaceuticals (NASDAQ:DAWN) Hits New 12-Month Low Following Weak EarningsFebruary 26, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)Needham & Company LLC reissued a "buy" rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday.February 26, 2025 | marketbeat.comHC Wainwright Has Lowered Expectations for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock PriceHC Wainwright lowered their target price on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a "buy" rating for the company in a report on Wednesday.February 26, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Day One Biopharmaceuticals (DAWN)February 26, 2025 | markets.businessinsider.comDay One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comDay One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate ProgressFebruary 25, 2025 | globenewswire.comDay One Biopharmaceuticals Inc (DAWN) Q4 2024 Earnings Report Preview: What To Look ForFebruary 25, 2025 | finance.yahoo.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells 4,370 Shares of StockDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CFO Charles N. York II sold 4,370 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the transaction, the chief financial officer now owns 252,638 shares of the company's stock, valued at $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.February 22, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow Sells 4,646 SharesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) General Counsel Adam Dubow sold 4,646 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the transaction, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.February 22, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender Sells 12,048 SharesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CEO Jeremy Bender sold 12,048 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares of the company's stock, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.February 22, 2025 | marketbeat.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells 4,370 Shares of StockFebruary 22, 2025 | insidertrades.comTimesSquare Capital Management LLC Sells 116,769 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)TimesSquare Capital Management LLC trimmed its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 6.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,710,926 shares of the company's stock after sFebruary 20, 2025 | marketbeat.com Remove Ads Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Media Mentions By Week DAWN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼0.800.78▲Average Medical News Sentiment DAWN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼114▲DAWN Articles Average Week Remove Ads Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SpringWorks Therapeutics News Today Protagonist Therapeutics News Today Catalyst Pharmaceuticals News Today Merus News Today Alvotech News Today Apellis Pharmaceuticals News Today Scholar Rock News Today Crinetics Pharmaceuticals News Today Immunovant News Today ACADIA Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DAWN Stock Free DAWN Stock Alerts